Trinity Biotech (TRIB) has released an update.
Trinity Biotech reported a 3% increase in Q3 2024 revenue to $15.2 million, driven by strong demand for its TrinScreen HIV business. The company also highlighted significant growth in its Point-of-Care product revenue, which surged by 60% year-over-year. Furthermore, Trinity Biotech is progressing with strategic initiatives aimed at enhancing profitability, including consolidating manufacturing operations and expanding into the oncology diagnostics market.
For further insights into TRIB stock, check out TipRanks’ Stock Analysis page.
